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Telomerase is a highly specialized reverse transcriptase (RT) and the maintenance of telom-
eric length is determined by this speciﬁc enzyme.The human holoenzyme telomerase is a
ribonucleoprotein composed by a catalytic subunit, hTERT, an RNA component, hTR, and
a group of associated proteins. Telomerase is normally expressed in embryonic cells and
is repressed during adulthood.The enzyme is reexpressed in around 85% of solid tumors.
This observationmakes it a potential target for developing drugs that could be developed for
therapeutic purposes.The identiﬁcation of the hTERT as a functional catalytic RT prompted
studies of inhibiting telomerase with the HIV RT inhibitor azidothymidine (AZT). Previously,
we have demonstrated that AZT binds preferentially to telomeres, inhibits telomerase and
enhances tumor cell senescence, and apoptosis after AZT treatment in breast mammary
adenocarcinoma cells. Since then, several studies have consideredAZT for telomerase inhi-
bition and have led to potential clinical strategies for anticancer therapy.This review covers
present thinking of the inhibition of telomerase byAZT and future treatment protocols using
the drug.
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INTRODUCTION
Telomerase is a ribonucleoprotein that elongates the telomeres
in eukaryotic cells. The enzyme is composed of a catalytic sub-
unit, hTERT, a RNA component, hTR, and a group of associated
proteins. Based on experiments in ﬁbroblasts, in the absence of
telomerase, cellular telomeres are seen to shorten with an increas-
ing number of cell divisions. It was suggested that the lost of
telomeres could account for cell senescence after a given number
of duplications (Harley et al., 1991).
Studies on ﬁbroblasts cultures have indicated that telomeric
length could be used to predict the replicative capacity of these cells
(Allsoop and Harley, 1995). It was proposed that the lost of telom-
eric repeats, when a critic telomeric length was reached, induced
a signal that inﬂuences the cell cycle process and replicative senes-
cence (Campisi, 1997). According to this model, telomeres act
as a mitotic clock that determines the replicative life of a cell
(Vaziri and Benchimol, 1998). The use of the telomeric length as a
marker of the cells’ replicative history has been also described by
Chang and Harley (1995) who demonstrated that telomeric length
decreases in function of the passages of endothelial cells in culture.
Later, Bodnar et al. (1996) showed that the reintroduction of the
catalytic compound of telomerase in primary human ﬁbroblasts
and endothelial cells that lack telomerase activity elongated the
telomeric repetitions resulting in signiﬁcant increases in replicative
cell life.
Telomerase is active in the germ line and stem cells but is inac-
tive in most somatic cells. However, telomerase activity is found
in most immortalized cell lines and in 85–90% of human tumors.
It was also reported that telomerase activity was present in 90 of
101 biopsies that represented 12 human tumor types, but none in
50 normal somatic tissues (Dhaeene et al., 2000).
3′-Azido-2′,3′-dideoxythymidine [azidothymidine (AZT) or
zidovudine], is a thymidine analog (Figure 1) used in the
treatment of AIDS, since it blocks the replication of human
immunodeﬁciency virus-1 (HIV-1) by competitively inhibiting
reverse transcriptase (RT). It is phosphorylated intracellularly to
AZT-triphosphate (AZT-TP) by thymidine kinase, and is ﬁnally
incorporated into viral DNA blocking chain elongation by RT
(Falchetti et al., 2005). AZT-TP can also be incorporated into
eukaryotic DNA in place of thymidine, although it has low afﬁn-
ity for DNA polymerases α, β, and γ and high afﬁnity for RT
(Faraj et al., 2000). The identiﬁcation of the hTERT component of
telomerase as a functional catalytic RT, structurally similar to HIV
RT, prompted studies about the feasibility of inhibiting telomerase
with known RT viral inhibitors, such as AZT (Hájec et al., 2005).
AZT INHIBITION
Strahl and Blackburn (1994) demonstrated in Tetrahymena ther-
mophila that AZT shortened its telomeres by decreasing the de
novo telomere addition. In the same year it was demonstrated that
there are strong links between telomerase activity and cancer (Kim
et al., 1994). These two pioneering papers led to the speculation
that AZT could be acting upon the telomere/telomerase complex
in cancer cells.
In spite of the low afﬁnity of AZT for mammalian DNA poly-
merases, the drug can be incorporated into eukaryotic DNA.
Furthermore itwas demonstrated thatAZTwas preferentially inte-
grated into the telomeric region of CHO DNA using immunoﬂu-
orescence labeled antibodies against AZT (Olivero and Poirier,
1993). In 1995, we developed a methodology to quantitate the
preferential incorporation of AZT comparing the amount of [3H]-
AZTbound to telomeric andnon-telomeric sequences of CHOcell
DNA (Gomez et al., 1995).
Brieﬂy, telomeric DNA was separated from genomic DNA
by digesting with restriction enzymes and size fractionation.
We quantitatively compared the amount of [3H]-AZT bound
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FIGURE 1 | AZT structure.
to telomeric and non-telomeric sequences of CHO cell DNA.
DNA from cells exposed to 800 μM of [3H]-AZT for 24 h was
digested with a mixture of restriction enzymes, frequent cutters
in the overall genome, without restriction sites in the telom-
eric repeat (Sau3AI, AluI, and RsaI). The digest was then loaded
into Chroma Spin-1000 columns to isolate fragments of 1 kb
and upward. The ﬁrst fraction to be eluted was characterized
as the telomeric fraction (TF) whereas the non-telomeric frac-
tion (NTF) eluted later in second place. TF was comprised of
longer sequences (>2 kb) compared to NTF. This was conﬁrmed
by a Southern blot using a human telomeric probe. Radioactiv-
ity associated with each fraction revealed a threefold increase in
[3H]-AZT incorporated in the TF compared to NTF. No prefer-
ential telomeric binding was detected for [3H]-thymidine (Tdr)
or [H-3]-5′-bromodeoxyuridine (BrdU) in similar experiments.
The failure of thymidine or BrdU to preferentially incorporate
into telomeric repeats supported the hypothesis that differential
incorporation of AZT into TF was not a direct result of the telom-
eric sequence itself but most probably a phenomenon related
to the speciﬁcity of a polymerase such as telomerase. Primary
cultures of mouse dermal ﬁbroblasts, cells with large telomeric
repeats that lack telomerase, did not preferentially incorporate
AZT into the TF. Bal 31 digested DNA consists of mononu-
cleotides, including AZT, from both 3′ termini of the two strands
of linear DNA. When the chromosomal ends of high molecular
weight [3H]-AZT-DNA were digested with Bal 31, the radioac-
tivity was double in the TF (short-term digest) compared with
the NTF (longer digestions). Therefore incorporation of AZT in
CHO immortalized cells but not in primary ﬁbroblasts (that lack
telomerase) indirectly showed that AZT incorporation could be
telomerase-mediated.
Later, using different experimental models different groups
demonstrated thatAZT inhibited telomerase and/or reduce telom-
erase length. Strahl andBlackburn (1996) showed the effect of AZT
on the telomere length and cell growth properties of two immor-
talized human lymphoid cell lines, the B cell line JY616 and the
T cell line Jurkat E6-1. They found that passaging in the presence
of 100 μM AZT caused marked progressive telomere shortening
over several weeks in some but not all T andB cell cultures, without
changing cell growth rates. Telomerase activity was present in both
cell lines and was inhibited in vitro by AZT (Strahl and Blackburn,
1996). At the same time, Yegorov et al. (1996) reported that the
spontaneous transformation of mouse embryonic ﬁbroblasts in
the presence of AZT led to the formation of telomerase-free clones
after 3 months treatment. AZT induced senescence-like processes
in cultures of immortal mouse ﬁbroblasts. After long-term incu-
bations, cell proliferation gradually decreased, their morphology
becoming similar to that of the senescent cells. The process was
reversible: after inhibitor removal, the cells entered mitoses. One
or two weeks after AZT removal large mitotic cells were observed.
Moreover, standard karyotyping revealed that these cells were
polyploid. It was concluded that AZT block telomerase function
in mouse cells (Yegorov et al., 1996). Later, Olivero et al. (1997)
studied the transplacental effects of AZT in mice and monkeys
founding shorter chromosomal telomeres in liver and brain tis-
sues from most AZT-exposed newborn mice. Melana et al. (1998)
investigated the effect of AZT in four breast cancer cell lines, T4
leukemia, and a normal breast cell line in vitro. AZT inhibited the
growth of all tumoral cell lines, covering a wide range of concen-
trations. The IC50 varied from 0.25 to 1.35 mM for the cancer
cell lines and no correlation of IC50 with the rate of cell growth
was noted. Variations in IC50 may reﬂect differences in absorp-
tion, excretion, and/or phosphorylation of AZT between the cell
lines. Furthermore, they found that AZT inhibited colony for-
mation in soft agar and telomerase activity (Melana et al., 1998).
Similarly we showed for the ﬁrst time, that telomere shortening by
AZT was an irreversible process, suggesting that telomerase activ-
ity was possible after removal of the drug from the culturemedium
(Gomez et al., 1998).
In these experiments we subjected HeLa cells to long-term
exposure with AZT to evaluate telomere shortening and if so, the
reversibility of the phenomenon. The shortening of the telomeric
sequences of HeLa cells cultured with 800 μM AZT was observed
after 15 passages. Southern blots of HeLa DNA cultured with
Frontiers in Oncology | Cancer Molecular Targets andTherapeutics September 2012 | Volume 2 | Article 113 | 2
“fonc-02-00113” — 2012/9/10 — 18:45 — page 3 — #3
Gomez et al. AZT, telomerase inhibitor
AZT and digested with Sau3AI, AluI, and RsaI revealed a pro-
gressive shortening of the telomeric repeats when probed with a
human biotinylated telomeric probe. The shortening appeared to
be linear with time in culture and was irreversible, because the
shortened telomeric repeats were not elongated after culturing in
the absence of AZT for 25 additional passages. Fluorescence in situ
hybridization was also performed in cells growing with or without
AZT. Bright spots representing hybridization of ﬂuorescent telom-
eric probes to the telomeres were noted and weaker signals were
observed in cells exposed to AZT as compared to untreated cells.
No evidence of senescence could be detected. Markers of senes-
cence such as p21 (Waf1), small proline rich proteins (spr), and
apoptosis, were analyzed after AZT treatment. The results were
indistinguishable from the control untreated cells or the recovered
cells with no morphological or biochemical changes attributable
to senescence being observed. The fact that telomere length was
decreased in HeLa cells after long-term exposure to AZT with-
out any evidence of senescence could be the result of different
mechanisms. Firstly, the number of AZT-treated passages could be
insufﬁcient for a senescence program to be triggered, and secondly
telomeres shortening to a critical length could induce a compen-
satory mechanism of preservation so preventing further losses,
known as alternative lengthening of telomeres or ALT (Gan et al.,
2002). Thirdly, an AZT-resistant phenotype could have developed
as a result of selection following the treatment.
More recently evidence supporting the above view has been
presented, for example, Multani et al. (1998) using ﬂuorescence
in situ hybridization found a reduction of telomeric signals in
murine melanoma (K-1735 clone X-21) and human breast cancer
cell line (MCF-7) treated with AZT. Similar results were observed
in human endometrial carcinoma cells (HEC-1) whereas inhibi-
tion of telomerase activity and telomere length were seen to be
dependent on the AZT concentration and duration of exposure.
The same authors also found that in HEC-1 cells the effects of
cisplatin were enhanced with a marked reduction in cell prolif-
eration, appearance of morphological changes and senescent-like
cells in the presence of AZT (Murakami et al., 1999). Similarly,
synergistic interactions between paclitaxel and AZT (Johnston
et al., 2003) and between AZT and 5-ﬂuorouracil (Brown et al.,
2003) were described. Beltz et al. (1999) evaluated the effectiveness
of AZT in leukemic cell lines and blood lymphocytes founding
in the presence of the drug that cell growth was decreased and
that AZT inhibition was manifested at 48–96 h after addition
to the cultures. The inhibition was partially to totally reversible
upon inhibitor removal, indicating that AZT was not cytotoxic
but only suppressed cell growth temporarily (Beltz et al., 1999).
Similarly, Haïk et al. (2000) found that AZT blocked in a dose-
dependant manner the FGF2-induced proliferation of neural
precursor cells.
In 2001 we investigated the effects of chronic in vitro AZT
exposure on F3II mouse mammary carcinoma cells. Treatment
with 800 μM AZT for at least 30 passages completely inhib-
ited telomerase activity on F3II mammary carcinoma cells. We
demonstrated, for the ﬁrst time, that AZT-treated tumor cells
have a reduced tumorigenicity in syngeneic BALB/c mice. Tumor
incidencewas reduced and survivalwas prolonged in animals inoc-
ulated with AZT-treated cells compared to control. The number
and size of spontaneous metastases were also decreased in animals
inoculated with AZT-treated cells. In addition, we presented mor-
phological and biochemical evidence indicating senescence. At
passage 34, F3II cells acquired the rounded and enlarged morphol-
ogy characteristic of senescent cells. Histochemical staining with
the senescence biomarker SA-β-galactosidase was positive in AZT-
treated cells. To evaluate whether replicative senescence produced
by long-term AZT treatment leads to apoptosis, caspase-3 activity
was measured and found to signiﬁcantly increase in AZT-treated
tumor cells with 2.6-fold greater activity compared to control
cells after more than 50 in vitro passages in the presence of the
compound. In a different set of experiments, animals receiving
2 × 105 tumor cells were sacriﬁced on day 60, and s.c. tumors
and lungs were evaluated. The mitotic index was similar in both
control and treated groups. Accordingly, there was no difference
in PCNA expression. However, the apoptotic index was dramati-
cally increased in tumors originated from AZT-treated cells. Our
observations provided direct evidence that chronicAZT treatment
may be sufﬁcient to reverse tumor cell immortality and cause a
senescent and apoptotic phenotype (Tejera et al., 2001).
Similar results were found using other tumor lines including
parathyroid cancer cells (Falchetti et al., 2005) and hepatocellular
carcinoma in rats (Jeng et al., 2011). In respect to apoptosis, Ji
et al. (2005) described that the telomerase subunits, hTERT and
c-Myc were the ﬁrst to show reduced activity after AZT treatment,
followed by changes in hTR, Mad1, and hTEP1. Later, Fang and
Beland (2009) using a hepatoma cell line (HepG2) indicated that
AZT caused a decrease in checkpoint kinase 1 (Chk1) and kinase
2 (Chk2) and an increase in phosphorylated Chk1 (Ser345) and
Chk2 (Thr68).
CONCLUSION
Due to the structural and mechanistic similarities between telom-
erase and HIV-1 RT, it has been postulated that known RT
inhibitors may potentially inhibit human telomerase. The exper-
imentational results outlined here support this view. However,
doses and time of treatment are varied and the precise mechanism
of AZT action still remains elusive. AZT by itself could produce
a speciﬁc inhibition of telomerase by other means, independently
of its action as a chain terminator. For instance, p53 seems to
have a role in telomerase inhibition by AZT but more studies
are required to strengthen this view (Datta et al., 2006). Lately, a
number of non-telomeric telomerase functions as transcriptional
modulation of the Wnt-β-catenin signaling pathway and RNA-
dependent RNA polymerase activity have been described but so
far theyhavenot been conclusively linked toproviding antitumoral
effects. More experimental work is required to see its potential role
in tumor biology.
Two main considerations should be taken into account regard-
ing the antitumorigenic potential of the drug. First, as other
chemotherapeutic agents,AZT appears to have, under certain con-
ditions, potential tumorigenic properties (Olivero et al., 1997).
Second, as the shortening of telomeres is a slow process, the
dynamics of the disease could put at risk the life of the patient
before the action of AZT is fully functional.
The most appealing criticism (which is still purely speculative)
is the clinical relevance of inhibiting telomerase in cancer patients.
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Table 1 | Cancer clinical trials using AZT.
Scheme Reference Notes
AZT Marchbanks et al. (1995) Phase I in patients with solid tumors
AZT + methotrexate Miller et al. (1996) Phase II in advanced adenocarcinoma of pancreas and hepatocellular carcinoma
AZT + cis-diamminedichloroplatinum Morgan et al. (2003) Phase I in patients with advanced malignancies
AZT + 5-ﬂuorouracil + leucovorin Posner et al. (1992) Phase I in advanced malignant tumors
AZT + 5-ﬂuorouracil + leucovorin Clark et al. (1996) Phase II in metastatic colorectal cancer
AZT + 5-ﬂuorouracil + leucovorin Falcone et al. (1997) Phase II in metastatic colorectal cancer
According to the paradigm currently proposed for telomeres and
telomerases, it can be predicted that telomerase inhibition will not
affect a tumor until its telomeres reach the critical size for enter-
ing senescence. This means that during anti-telomerase therapy,
the tumor cells will continue to grow undergoing 20–30 divisions
until the telomeres reach a critical size leading to tumor senes-
cence. Therefore, concerns must be expressed when attempting to
treat advanced tumors with AZT (Lavelle et al., 2000). However,
this mode of treatment could constitute a good adjuvant therapy
in cases where conventional treatments reduce the bulk of tumor
mass giving time forAZT to act in attacking the remnant surviving
tumor cells.
Azidothymidine is used to treat several virus-associated human
cancers, including AIDS-related Kaposi sarcoma, Kaposi sarcoma-
associated primary effusion lymphoma, Epstein–Barr-associated
lymphoma, primary central nervous system lymphoma, and adult
T cell leukemia (Datta et al., 2006). As shown in Table 1 in
non-viral tumors, AZT has been used in phase I and II clinical
trials alone or in combination with other drugs for gastrointesti-
nal cancers, pancreatic cancer, and other advanced malignancies
with some tumor regression being reported (Posner et al., 1992;
Marchbanks et al., 1995; Clark et al., 1996; Miller et al., 1996;
Falcone et al., 1997). Although extremely promising, more clin-
ical trials using AZT are needed to understand the full potential of
this agent in a clinical setting.
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